Torisel Approved for Renal Cell Carcinoma Treatment
Torisel (Temsirolimus) was yesterday approved by the FDA for use in the treatment of renal cell carcinoma, a form of advanced kidney cancer.
Common adverse reactions associated with this drug include edema, loss of appetite, nausea, mouth sores, fatigue, and rash. The drug can also cause some abnormal lab test results, including high blood sugar, lipids and triglycerides, low red blood cell, white blood cell, and platelet counts, and elevated liver and kidney function tests.
Torisel is manufactured by Wyeth Pharmaceuticals and will be available in July 2007.
Photo courtesy of striatic